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Abstract
Transgender persons are at high risk for HIV infection, but prevention efforts specifically targeting 
these people have been minimal. Part of the challenge of HIV prevention for transgender 
populations is that numerous individual, interpersonal, social, and structural factors contribute to 
their risk.
By combining HIV prevention services with complementary medical, legal, and psychosocial 
services, transgender persons’ HIV risk behaviors, risk determinants, and overall health can be 
affected simultaneously. For maximum health impact, comprehensive HIV prevention for 
transgender persons warrants efforts targeted to various impact levels—socioeconomic factors, 
decision-making contexts, long-lasting protections, clinical interventions, and counseling and 
education.
We present current HIV prevention efforts that reach transgender persons and present others for 
future consideration.
Transgender persons are those whose gender identity does not conform to gender norms and 
expectations traditionally associated with their sex assigned at birth. Cisgender persons are 
those whose gender identity conforms to their birth sex. A 2008 synthesis of published US 
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studies reported that HIV rates among Black, White, and Hispanic transgender women 
(assigned “male” at birth) were 56%, 17%, and 16%, respectively.1 These figures are higher 
than or comparable with 2011 HIV rates among Black, White, and Hispanic men who had 
sex with men (36%,15%,and 17%,respectively)2 and Blacks, Whites, and Hispanics in 
general (42%, 4%, and 12%, respectively).3 HIV infection rates among transgender men 
(assigned “female” at birth) have been difficult to determine,4,5 but estimates range from 0% 
to 3%.1 Separate rates for nonbinary transgender persons are not available as data on this 
subgroup are limited.6
The United States’ National HIV/AIDS Strategy notes that transgender persons are at high 
risk for HIV infection and efforts specifically targeting transgender populations have been 
minimal.7 Given the complex determinants of HIV infection among transgender persons, 
preferable prevention strategies likely will be comprehensive—a combination of structural, 
biomedical, and behavioral interventions with demonstrated efficacy in reducing HIV 
infection.
We summarize the nature of transgender persons’ risks for HIV infection, present the best-
evidence prevention that is available and how to apply that prevention in transgender-
specific and sensitive ways, and elaborate on immediately available options for a 
comprehensive HIV prevention approach for transgender people.
DETERMINANTS OF HIV
Transgender adults and adolescents, regardless of HIV status, have many individual, 
interpersonal, social, and structural factors contributing to HIV infection risk, not all of 
which are unique to their gender identity.8 Individual and interpersonal factors contributing 
to HIV infection for transgender women and men are presented in Table 1. Although HIV 
rates among transgender men are currently low, their risk is not negligible. Other individual 
and interpersonal factors for transgender persons overall include sexual assault (64%), 
physical abuse (61%), and lack of familial support (57%).12
In addition to these factors, transgender persons experience more social stressors than 
cisgender persons. Social and structural factors creating stress among transgender persons 
include unemployment (66% transgender women, 4% transgender men), stigma and 
discrimination (63% overall), and homelessness (19% overall, 57% transgender 
women).1,11,12 Stressors are compounded by discrimination on the basis of one’s social 
identity (e.g., race, class, gender expression, immigration status). The health and well-being 
of transgender persons is influenced by these factors and social stressors over their life 
course, creating unique dynamics requiring transgender-sensitive prevention approaches.
HIV infection among transgender persons is generally attributed to engaging in condomless 
receptive intercourse with cisgender men who have sex with men (Table 1).1,4 Transphobia, 
employment discrimination, and expensive gender reassignment procedures (GRPs), both 
hormonal and surgical, create financial hardships among transgender women that can lead to 
agreeing to commercial sex with customers who pay more to have condomless sex.13 
Transgender men engage in sex work to affirm their male identity and to earn money for 
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GRPs.4,5 Not having been socialized in the gay community, transgender men may not know 
how to negotiate safe sexual practices with their male partners who have sex with men.4,5 
Some transgender men who use testosterone may experience increased libido and vaginal 
dryness, both of which elevate their HIV risk.14,15 Transgender persons may forgo condoms 
with their primary sexual partners for gender identity affirmation.13 This is concerning 
because condoms are sometimes not used with primary partners with discordant HIV status.
Transgender persons could become infected with HIV from sharing syringes to inject drugs, 
hormones, or silicone, although they may be more likely to acquire HIV by having sex with 
a partner who injects drugs.16 General drug and alcohol use is common and may be used to 
cope with gender dysphoria, stress, and anxiety and to make engaging in sex work easier.13 
Drug and alcohol use may also play a role in acquiring or transmitting HIV infection by 
undermining the will or ability to negotiate safer sexual practices.
HIV is only one of many public health problems occurring in the transgender community.7 
Other public health conditions prevalent in that community include discrimination-based 
physical and verbal abuse and homicide; poor mental health, including depression and 
suicidal thoughts; alcohol and drug use; economic marginalization; and unmet health care 
needs resulting from limited health care access and negative health care encounters.1,17 
These co-occurring problems may additively increase sexual risk. Operario and Nemoto8 
argue that these conditions indicate co-occurring epidemics that interact and reinforce each 
other and call for bundling of HIV prevention services with complementary health and social 
services that are synergistic in their health benefit, cost-effective, and accepted by the 
transgender community. Such programs would benefit from fostering resiliency among 
transgender persons by providing supportive role models and incorporating resilience 
strategies, such as belief in natural diversity in sexual orientation and gender identity, a right 
to define one’s own gender identity, taking strength from surviving adversity, cultivating 
hope for the future, finding safe places, and connecting with a supportive community.
HIV PREVENTION
We present HIV prevention interventions for transgender persons organized according to the 
five tiers of Frieden’s18 Health Impact Pyramid. The base of the pyramid represents public 
health strategies that reach large numbers of people and require little effort from individuals 
receiving the benefit and, thus, have the potential for largest impact. At each progressively 
ascending tier of the pyramid, the numbers reached decreases and individual effort increases 
and, consequently, the strategies have decreasing potential impact.
Behaviors, context, and socioeconomic determinants are factors associated with high rates of 
HIV infection. Adding approaches to current strategies and addressing these factors 
comprehensively, instead of individually or partially, are more likely to maximize health 
impact among transgender persons. The line between “current” (widely available) and 
“future” (less common or nonexistent) interventions varies by location.
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Socioeconomic Factors
Interventions that change social determinants of health form the base tier of the pyramid. 
Such interventions reach people collectively and include promoting social justice, improving 
economic opportunities and educational attainment, and increasing access to services.18 
Transgender persons may benefit from policies applied to the general public. Examples 
include living wage ordinances, public transportation, distribution of free condoms, laws 
permitting pharmacy sale of syringes, interpreter services, and health insurance coverage 
under the Patient Protection and Affordable Care Act.19 However, transgender persons must 
find sensitive and experienced providers, and insurance coverage for GRPs is uncommon.20 
We could not identify HIV prevention efforts at this level that target transgender people.
Future prevention efforts to address underlying social determinants of health for transgender 
persons could consider including
1. general equivalency diploma (GED) programs, job training programs, and 
English language education;
2. housing programs;
3. physically safe social venues and activities;
4. transgender-sensitive health care and mental health services;
5. legal services with expertise in transgender and immigration issues;
6. sentencing diversion programs;
7. cohesive transgender communities and social organizations;
8. policies that do not force binary gender selection; and
9. health insurance that covers GRPs and all physical sex–related care (e.g., 
Papanicolaou smears for transgender men).
Organizations could consider providing supportive services, such as HIV and hepatitis C 
testing, sexuality education, clothing, and referrals, for example, to substance abuse 
treatment, GED programs, and employment and legal services. Legal services could provide 
assistance with nondiscrimination protections and changing names and gender markers on 
identity documents. Monitoring HIV/AIDS prevalence, incidence, and prevention needs of 
local transgender populations may likely be improved by collecting epidemiologic data, 
including the two-question method for assessing gender,21 and separating transgender 
identities in reports.
Changing Context to Foster Healthy Decisions
The pyramid’s second tier represents interventions that change the environmental context for 
a population so that healthy options are the collective default choice. Non–HIV-related 
interventions at this level include clean water, road improvements, and smoke-free laws.18 
We could not find widespread second-tier HIV prevention efforts specifically for transgender 
people. However, transgender persons benefit from policies applied to the general 
population, such as opt-out HIV screening.
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Future interventions to change the environmental context for transgender people might 
appropriately include
1. programs to decrease violence against transgender persons;
2. sensitivity training for law enforcement and corrections officers with prohibition 
of profiling and harassment;
3. sensitivity training for school officials;
4. gender-affirming policies in correctional facilities;
5. laws prohibiting transgender discrimination in employment, housing, and social 
services; and
6. routine sexually transmitted infection and HIV testing in medical settings.
Social marketing campaigns to eliminate stigma and discrimination may change community 
norms and improve availability and acceptability of healthful options for transgender 
persons. Behavioral economic interventions targeting transgender persons, such as 
conditional economic incentives for remaining free of sexually transmitted infections, could 
be researched as temporary alternatives to exchanging sex for basic needs.22
Long-Lasting Protective Interventions
Third-tier interventions are those that are directed toward individuals one time or 
infrequently and do not require ongoing clinical care.18 An HIV prevention intervention at 
this level is male circumcision, which can decrease HIV acquisition for cisgender males.23 
Male circumcision’s applicability to transgender persons may be limited to persons who 
were assigned male and who have not undergone gender reassignment surgery. Transgender 
persons may benefit from interventions for the general population (e.g., immunizations for 
hepatitis A and B and human papillomavirus), depending on their sexual and injection 
practices. To increase their safety in public settings and in relationships, transgender persons 
may choose to have voice and communication therapy or training in their presenting 
gender’s social and relationship skills.
Future long-lasting, protective interventions for transgender persons could include peer 
support groups. Although not intended as HIV prevention interventions, medically 
administered hormones and gender reassignment surgery could avoid unsafe injection 
practices and improve mental health and associated risk behaviors.14 In a recent study, 
postoperative transgender women were less likely to have condomless anal sex, a practice 
with a high risk of HIV transmission, compared with preoperative transgender women.24
Clinical Interventions
The fourth tier of the pyramid represents ongoing, evidence-based clinical care for 
individuals.18 Current HIV prevention at this level includes biological (e.g., antiretroviral 
therapy [ART], pre-exposure prophylaxis [PrEP], vaginal and rectal microbicides) and 
behavioral (e.g., substance abuse treatment, mental health services) interventions.7 Although 
biological interventions can lower community viral load and prevent HIV disease 
progression, transmission, and acquisition, their effect is limited by lack of access to clinical 
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care, insufficient medication adherence, and imperfect effectiveness of the interventions. 
Fourth-tier HIV prevention efforts specifically for transgender persons are presented in the 
Substance Abuse and Mental Health Services Administration’s guidance on providing 
culturally competent services.25 Transgender persons may benefit from ART and PrEP, but 
can experience decreased response to hormone replacement therapy (HRT) if they are on 
ART.15
Suggested future clinical interventions for transgender persons could include
1. training for improved provider attitudes and behavior toward transgender 
patients;
2. increased availability of gender-affirming, knowledgeable, and transgender-
specific and -sensitive medical care;
3. increased availability of transgender-sensitive substance use and alcohol 
dependence treatment;
4. insurance coverage for gender dysphoria; and
5. receiving HRT and ART or PrEP from the same provider to encourage HIV care 
and prevention.14
Although not an HIV prevention intervention, medically managed HRT could enhance 
transgender persons’ mental health,14 and HIV testing or monitoring could be done during 
HRT appointments. Mutual patient–provider trust is essential for transgender persons to 
discuss their treatment challenges, HIV risk behaviors, and gender reassignment history. If 
transgender persons do not disclose their sex assigned at birth, providers may base 
examinations on presenting gender and not perform necessary health screenings (e.g., for 
prostate cancer).
Counseling and Education Interventions
The fifth tier represents health education provided to individuals in clinical visits or other 
settings.17 Counseling and education interventions seek to discourage unhealthy or risky 
behaviors and to encourage healthy or safer behaviors. Individual effort is high in this tier 
and increases with each intervention session. Although changing environmental context has 
more population influence, counseling and education interventions are more feasible.18 
Systematic reviews have shown that evidence-based interventions (EBIs) are efficacious in 
reducing HIV-related risk behaviors and in increasing protective behaviors among at-risk 
populations.1 However, the Centers for Disease Control and Prevention’s Compendium of 
Evidence-Based Interventions and Best Practices for HIV Prevention26 notes that currently 
there are no EBIs specifically designed for transgender participants. Although several 
interventions have been developed for transgender women,17,27–31 to date, few have been 
rigorously evaluated and two are undergoing randomized controlled trials.30,31 No 
interventions have been developed for transgender men.
Analyses by Herbst et al.1 indicate that future counseling and education interventions for 
transgender persons should contain
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1. referrals to housing, job training, legal, and medical services;
2. awareness of local antidiscrimination laws;
3. sexual and drug risk-reduction skills building; and
4. HIV counseling and testing.
Skills in coping with stress, disclosure of gender identity, and social behaviors of the 
presenting gender may also be beneficial. If these components are not covered by an EBI, 
they could be incorporated as adaptations with input from transgender persons.32 However, 
extensive adaptation requires time and resources for formative research, incorporation of 
findings, and evaluation of the reinvented intervention.
To minimize adaptation effort, HIV/AIDS service organizations could select EBIs that target 
risk behaviors and determinants common to the organization’s transgender clients and that 
match the organization’s implementation capacity. To aid EBI selection, we searched the 
Centers for Disease Control and Prevention’s list of EBIs26 to find those with 
implementation manuals. We read the manuals to identify EBIs that target any of the 
previously discussed HIV risk behaviors and determinants common to transgender persons. 
We identified 12 EBIs that address at least four of these factors (Table 2). It is likely that an 
organization’s transgender clients may need multiple EBIs to address all of their relevant 
HIV risk factors. Table A, available as a supplement to the online version of this article at 
http://www.ajph.org, presents implementation capacity considerations.
When one is adapting EBIs, sensitizing content is important— for example, terminology for 
sexual behaviors and pre- and post-GRP anatomy, non-anatomical models for condom skills 
practice, and suitable examples of risk-reduction goals and barriers. Service organizations 
may want to consider adding relevant content, such as HIV risk from shared injection of 
hormones, commercial sex work customers, appropriate risk scenarios, vulnerabilities from 
stage of physical transition and desire for gender affirmation, and referrals to transgender-
sensitive medical and social services. Depending on the EBI’s participants, organizations 
may consider omitting references to perinatal transfer, pregnancy, babies, breastfeeding, and 
pelvic inflammatory disease.
IMPLICATIONS
Because transgender persons’ risk of HIV infection is exacerbated by complex social 
determinants and intersecting social and gender identities, comprehensive HIV prevention 
for this population is warranted. For maximum health impact, comprehensive prevention 
programs that are developed by assessing the HIV prevention needs of local transgender 
persons, prioritizing at-risk transgender groups, identifying currently available interventions 
and services, and determining needed resources are more likely to be effective.
The Health Impact Pyramid may be useful for identifying gaps and selecting interventions at 
each tier for high-priority groups. Comparing interventions across tiers may ensure that 
interventions selected for higher tiers (e.g., referrals to transgender-competent health 
services) are supported by interventions at lower tiers (e.g., transgender care and sensitivity 
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training for clinicians). Bundling comprehensive HIV prevention services with 
complementary medical, legal, and psychosocial services can simultaneously affect 
transgender persons’ HIV risk behaviors, risk determinants, and overall health.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TABLE 1
Prevalence of Individual and Interpersonal Factors Contributing to HIV Among Transgender Women and 
Transgender Men: United States
Factors Transgender Women,1,9–11 % Transgender Men,1,4,9,10 %
Condomless receptive anal intercourse 44–69 13
Condomless insertive anal intercourse 5–27 17
Condomless receptive vaginal intercourse 5 17
Condomless insertive vaginal intercourse 6 23
Multiple sexual partners 32–73 17–34
Sex work, sexual exchange 11–42 0–31
Previous sexually transmitted infections 13–21 6–46
Injection drug use
 Inject drugs 1–12 4–21
 Share syringes for injecting drugs 2 NA
Hormone use
 Inject hormones 27 12–91
 Share syringes for injecting hormones 6 NA
Silicone use
 Inject silicone 25 …
 Share syringes for injecting silicone 6 …
Sex while drunk or high 39 NA
Depression 51 48
Anxiety 40 48
Note. NA = not available. Data in the table are from an unsystematic literature review. Statistical comparability is not implied.
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